Valuation: EyePoint, Inc.

Market Cap 3.1Cr 2.78Cr 2.54Cr 2.32Cr 4.38Cr 291.75Cr 4.51Cr 31Cr 12Cr 155.67Cr 12Cr 11Cr 491.44Cr P/E 2026 *
-0.1x
P/E 2027 * -0.18x
Enterprise Value -30Cr -27Cr -25Cr -22Cr -42Cr -2.82TCr -44Cr -296.09Cr -118.06Cr -1.5TCr -112.48Cr -110.07Cr -4.75TCr EV / Sales 2026 *
-176x
EV / Sales 2027 * -46.4x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day+1.15%
1 week+3.33%
Current month+3.33%
1 month-89.16%
3 months-97.41%
6 months-97.32%
Current year-98.03%
1 week 0.33
Extreme 0.3305
0.41
1 month 0.33
Extreme 0.3305
3.57
Current year 0.33
Extreme 0.3305
18.87
1 year 0.33
Extreme 0.3305
19.11
3 years 0.33
Extreme 0.3305
30.99
5 years 0.33
Extreme 0.3305
30.99
10 years 0.33
Extreme 0.3305
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%+3.33%-96.79%-95.29% 3.1Cr
-0.79%-4.48%+46.48%+125.69% 1,20600Cr
+1.43%+1.11%+48.05%+83.05% 66TCr
+1.07%-1.21%+32.92%+104.92% 51TCr
-0.36%-3.25%+45.42%+65.10% 38TCr
-0.14%-1.87%+70.06%+41.09% 36TCr
-0.78%-0.52%+30.47%+58.09% 31TCr
-0.80%-0.21%+7.98%+36.17% 29TCr
+0.03%-1.20%+43.79%+69.83% 25TCr
-0.41%-2.22%+40.43%+107.03% 21TCr
Average +0.04%-1.05%+26.88%+59.57% 41.8TCr
Weighted average by Cap. -0.04%-1.96%+42.71%+88.11%

Financials

2026 *2027 *
Net sales 17.03L 15.27L 13.96L 12.74L 24.01L 16Cr 24.76L 1.68Cr 67.09L 8.54Cr 63.92L 62.55L 27Cr 38.49L 34.52L 31.55L 28.8L 54.27L 36Cr 55.98L 3.8Cr 1.52Cr 19Cr 1.44Cr 1.41Cr 61Cr
Net income -33Cr -29Cr -27Cr -24Cr -46Cr -3.06TCr -47Cr -321.31Cr -128.12Cr -1.63TCr -122.07Cr -119.45Cr -5.15TCr -20Cr -18Cr -16Cr -15Cr -28Cr -1.86TCr -29Cr -195.87Cr -78Cr -994.37Cr -74Cr -73Cr -3.14TCr
Net Debt -33Cr -30Cr -27Cr -25Cr -47Cr -3.11TCr -48Cr -326.75Cr -130.29Cr -1.66TCr -124.13Cr -121.47Cr -5.24TCr -21Cr -19Cr -17Cr -16Cr -30Cr -1.97TCr -31Cr -207.28Cr -83Cr -1.05TCr -79Cr -77Cr -3.32TCr
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
06/26/06 $0.3600 +1.15% 59,80,174
05/26/05 $0.3559 -9.90% 42,20,902
04/26/04 $0.3950 -1.23% 30,66,828
03/26/03 $0.3999 +6.70% 35,12,441
02/26/02 $0.3748 +7.58% 63,27,727
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.3600USD
Average target price
8.438USD
Spread / Average Target
+2,243.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EyePoint, Inc.
  1. Stock Market
  2. Stocks
  3. EYPT Stock